Medical Device Startup Valuation Starts With the Number You Plan to Raise

Medical device startup valuation is tied directly to how much capital you're raising, how you plan to spend it, and how much dilution you can absorb at each stage.

Founders who treat the raise amount as a guess get a valuation that reflects that guess.

Key Takeaways

• Colleen Gray of US Capital says founders often pick a random raise number instead of working backward from what the company needs.
• The amount you raise and the valuation you get are linked. Raising more than you need can dilute the company more than necessary.
• Dilution has to be managed at every round, because decisions made early affect every round after.
• Who you raise from matters as much as how much you raise. An investor without industry knowledge creates problems later.
• Starting a capital raise late is a common and costly mistake, because the process takes longer than most founders expect.
• A capital raise costs money before the first check is signed, in visibility, public profile, and preparation.

Watch the full episode on YouTube

Medical Device Startup Valuation Starts With the Raise Amount Behind It

Medical device startup valuation is inseparable from how much money you're raising and why. A founder who can't explain the number walks into the valuation conversation already behind.

I interviewed Colleen Gray, Senior Vice President at US Capital, on an episode about medtech fundraising, valuation, and investor strategy. She named the mistake she sees most often:

"A lot of founders just kind of come up with this some random number. But it feels like that's the wrong way to go, because it could be that you need less money, and even if you need more, structuring how you're going to spend that money is going to be important based on the valuation you're going to get."

The raise amount and the valuation are one conversation, because an investor reading an unjustified number assumes the founder hasn't done the work to know what the company needs, and that assumption shapes the offer that comes back.

Gray points founders toward the same justification every time: time to commercialization, how much capital has already gone into the company, and what that capital produced. A founder who can show investors exactly what the last round bought is making the case for the next number instead of guessing at it.

Dilution Has to Be Managed Across Every Round a Company Expects to Raise

Decisions made at the earliest funding round still affect every round that follows, because dilution compounds rather than resetting each time.

Not every dollar a company needs has to come from equity. Gray pushes founders who are already generating revenue toward asset-based lines of credit and other non-dilutive financing before they default to another priced round, because debt against revenue doesn't cost the company equity the way a new raise does.

Gray described how the dilution conversation changes as a company moves through stages:

"You've got to be cognizant of dilution. In the early stage with the angels, you want to protect their interests. You're not going to overly dilute them. And when you're talking with VCs and maybe family offices, you really want to manage through the dilution situations you're going to encounter at every round."

A founder who over-dilutes early to hit a higher headline valuation is borrowing against every round that comes after. Investors at each subsequent stage read the cap table as closely as the pitch, and a cap table that shows early overdilution reads as a planning failure before the meeting even starts.

Who You Raise From Matters as Much as How Much You Raise

The investor behind the check matters as much as the number on it, because an investor without medtech experience creates problems a founder has to manage instead of problems the investor helps solve.

Gray has lived both sides of this. She described taking money early in her own entrepreneurial career from an investor with no healthcare background, who didn't understand the regulatory environment or how difficult hospital systems are to sell into. That mismatch turned ordinary operating decisions into fights that had nothing to do with the business.

Later-stage rounds can afford to bring in purely financial investors to complement a cap table that already has industry knowledge on it. But the earliest checks set the tone, because those are the investors a founder has to communicate with constantly while the company is still figuring out its market. Gray put it this way:

"An investor that is so far removed from the industry you're in, you really got to think twice about that if they're going to be your principal investor early on. The early investors have to have enough industry knowledge that you can connect with them, communicate well, and have them understand what you're up against."

Starting the Raise Late Costs More Than Founders Expect

A valuation conversation that starts under time pressure rarely goes well, because the capital raise itself takes longer than most founders plan for.

Gray opened the same episode with this exact warning:

"The one piece of advice I would say is don't wait too long to start your capital raise, because it's going to take longer than you think. Make sure you have a budget for that capital raise, because it's not going to be free."

A late start compresses the timeline for building investor relationships, so founders end up pitching to whoever is available rather than the investors best suited to the company.

Gray recommends founders give investors concrete near-term milestones to watch for, like a filing date or a deal about to close, so investors can see a founder predict something and then deliver it before the first check is even written. That process takes months, and starting it late is exactly where a company's negotiating position disappears.

What This Means for Medtech Founders

In my experience working with medtech founders, the valuation conversation goes better the earlier it's treated as a planning exercise instead of a negotiation.

Know the raise number and be able to defend it with what the last round accomplished. Track dilution across every round you expect to raise, and look at non-dilutive options like a line of credit before defaulting to another priced round.

Vet the investor as carefully as the investor vets the company; a principal investor with no medtech background creates friction that outlasts the check. Start the process months before the capital is needed, with a few concrete milestones investors can watch you hit along the way.

Medical device startup funding closes faster when category work happens pre-seed covers the groundwork that makes all four of those conversations easier.

Frequently Asked Questions

How does medical device startup valuation work?

Valuation is tied directly to the amount a company is raising and how clearly that number is justified. Investors weigh the raise amount, the planned use of funds, and the company's dilution history, not just the clinical story. A founder who can show what a previous round produced gets a stronger number.

What's the biggest mistake founders make with valuation?

The biggest mistake is picking a raise amount without working backward from what the company needs. An unjustified number signals to investors that the founder hasn't done the planning work, which affects the valuation offered in response. Grounding the number in time to commercialization and what prior capital has already achieved solves it.

Why does dilution matter across multiple funding rounds?

Overdiluting at an early round limits a founder's position at every round after it. Investors at later stages review the cap table, and heavy early dilution reads as a planning problem before the founder even presents. Non-dilutive options like asset-based lines of credit can reduce how much equity a company has to give up to keep growing.

When should a medical device startup start raising capital?

Earlier than most founders expect. The fundraising process takes longer than anticipated, and starting late compresses the time available to build the right investor relationships, which weakens a founder's position during the negotiation. Investors also want to watch a founder hit a few forecasted milestones before they write a check, which takes months a late start doesn't leave.

Where to Go From Here

If you're doing this yourself. Run your raise number and narrative through the Pitch Deck Analyzer to see whether the story matches the number you're asking investors to fund.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. For founders preparing to raise, the audit flags whether the raise number and the narrative line up.

Listen to the Full Conversation

Colleen Gray's full conversation with Omar Khateeb is available on The State of MedTech. Watch on YouTube. Subscribe wherever you listen to podcasts.

About Colleen Gray

Colleen Gray is Senior Vice President at US Capital, where she works with medtech founders on capital raises and investor strategy. She has experience on both sides of the fundraising table, having worked as an entrepreneur before moving into investment banking.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth.

Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.